MedTrace Logo

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

NCT03219450 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-05-22

No results posted yet for this study

Summary

This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL)

The names of the study interventions involved in this study are:

* Personalized NeoAntigen Vaccine
* Poly-ICLC
* Cyclophosphamide
* Pembrolizumab

Conditions

  • Lymphocytic Leukemia

Interventions

DRUG

NeoVax

It stimulates the immune system to attack cancer cells.

DRUG

Cyclophosphamide

It is a chemotherapy drug used to treat many cancers. At low doses, it is an investigational drug to help the immune cells to be better at attacking cancer cells while avoiding chemotherapy toxicity.

DRUG

Pembrolizumab

Is a monoclonal antibody that helps the immune cells to be better at attacking cancer cells.

Sponsors & Collaborators

Principal Investigators

  • Inhye Ahn, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-18
Primary Completion
2027-05-31
Completion
2028-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03219450 on ClinicalTrials.gov